Jin-zhou L. Xu
No. 1095 Jiefang Avenue
Wuhan, 430030, China
Wuhan, 430030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Magnetically Navigated and PSMA/STEAP1 Dual-Targeted Nanoliposomes for NIR-II/MRI Imaging with Photothermal-Chemo-Immunotherapy for Prostate Cancer.
Journal: Research (Washington, D.C.)
Published: March 09, 2026
Corrigendum to "Escherichia coli Nissle 1917 outer membrane vesicles encapsulating oncolytic virus remodel tumor-associated macrophages and kill prostate cancer cells" [Journal of Controlled Release Volume 390, 10 February 2026, 114514/ COREL-D-25-06760].
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: January 22, 2026
Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system.
Journal: Journal for immunotherapy of cancer
Published: January 09, 2026
Escherichia coli Nissle 1917 outer membrane vesicles encapsulating oncolytic virus remodel tumor-associated macrophages and kill prostate cancer cells.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 26, 2025
Therapeutic translation of traditional Chinese medicine Huangqi derived exosome like nanoparticles: targeting prostate cancer through ferroptosis activation, immune reprogramming, and microbiome modulation.
Journal: Journal of nanobiotechnology
Published: August 07, 2025
Targeting the HSP60/p53 Axis with Extracellular Vesicle-Delivered siRNA Reprograms Glycolysis in Prostate Cancer.
Journal: International journal of biological sciences
Published: July 02, 2025
Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.
Journal: Journal of virology
Published: June 20, 2025
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database.
Journal: Expert opinion on drug safety
Published: June 04, 2025
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: March 28, 2025
A novel prostate cancer-specific fluorescent probe based on extracellular vesicles targeting STEAP1 applied in fluorescence guided surgery.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 13, 2024
Metabolic dysfunction-associated fatty liver disease as a mediator of urolithiasis risk: evidence from cross-sectional and genetic studies.
Journal: International journal of medical sciences
Published: November 12, 2024
Last Updated: 09/26/2026